只接受綜述和邀請(qǐng)?jiān)u論(評(píng)論和邀請(qǐng)?jiān)u論)。由現(xiàn)代醫(yī)藥集團(tuán)有限責(zé)任公司出版。ISSN(印刷):1523-3804。ISSN(電子):1534 - 6242。本雜志的目的是系統(tǒng)地為當(dāng)前動(dòng)脈粥樣硬化領(lǐng)域的基礎(chǔ)科學(xué)和臨床進(jìn)展提供專(zhuān)家意見(jiàn)，并強(qiáng)調(diào)可能改變心血管預(yù)防、診斷和治療領(lǐng)域的最重要的發(fā)展。為了達(dá)到這一目標(biāo)，我們?nèi)蚊艘恍┲饕臋?quán)威機(jī)構(gòu)作為欄目編輯，他們從世界各地挑選頂尖的專(zhuān)家，對(duì)過(guò)去一年發(fā)表的關(guān)鍵主題和論文進(jìn)行權(quán)威的評(píng)論。我們還提供該領(lǐng)域知名人士的補(bǔ)充評(píng)論。一個(gè)由國(guó)際不同成員組成的編輯委員會(huì)建議他們的國(guó)家/地區(qū)特別感興趣的主題，并確保主題是當(dāng)前的，包括新興的研究。

只接受綜述和邀請(qǐng)?jiān)u論（Reviews and Invited Commentaries）。Published by Current Medicine Group LLC. ISSN (printed): 1523-3804. ISSN (electronic): 1534-6242.The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.